Xlife Sciences AG discloses 16.3% stake in Veraxa Biotech from business combination
Xlife Sciences AG, a Swiss corporation, disclosed beneficial ownership of 23,029,967 ordinary shares of Veraxa Biotech Holding AG, representing 16.3% of the class, acquired in connection with the closing of a business combination. The shares carry sole voting and dispositive power. Under a Voting, Support and Lock-Up Agreement, Xlife Sciences agreed to restrictions on transfers for a specified period following the acquisition closing.
Key facts
- Xlife Sciences AG acquired 23,029,967 ordinary shares (16.3% of class)
- Shares acquired in connection with closing of business combination
- Reporting person subject to Voting, Support and Lock-Up Agreement restricting transfers for specified period
- Company shareholders may receive aggregate up to 5,000,000 earnout shares per fiscal year for three years based on volume-weighted average price thresholds of $11.00 (by Dec 31, 2026), $12.50 (by Dec 31, 2027), and $14.00 (by Dec 31, 2028)
Why it matters
Xlife Sciences is now Veraxa Biotech's largest disclosed shareholder following the de-SPAC transaction and is contractually restricted from transferring its shares for an initial lock-up period, limiting near-term liquidity in the public float.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from SCHEDULE 13D filed 2026-06-15. Not investment advice. View the source filing on SEC.gov →